The Nippon Chemiphar Group has been working to attain its three principal goals since 2000. In order to further advance the themes of those goals, the Group has created three main areas of business: generics, diagnostics, and new drugs.
By expanding these areas overseas, gradually attaining sustainable development, and maximizing our corporate value, I believe we can build a business model with incomparable value for all our stakeholders.

It is our view that our FY2023 financial results were significantly affected by temporary factors, such as the impact of shipment adjustments made in the third quarter of the previous fiscal year, which continued through the first half of FY2023; the sluggish allergy market, due to the lower-than-anticipated amount of airborne pollen in the fourth quarter; and the fact that the new drug out-licensing agreement that we expected to be concluded in the second half of the fiscal year did not result in a contract.

In fiscal 2024, we expect to achieve a return to profitability. Certainly, the Pharmaceutical Products segment faces the impact of drug price revisions, but the recovery trend from the second half of the previous fiscal year continues. In addition, we expect to gain further domestic market penetration for our DropScreen allergy screening kit, which has been growing remarkably in recent years. With the ongoing changes to the environment surrounding the Japanese economy and pharmaceutical industry, the Nippon Chemiphar Group’s goal is to contribute to society through our unique initiatives and thereby develop our business.

To the end, we will plan to continue making Company-wide efforts in its three areas of business to help patients suffering from diseases for which there is still no adequate treatment, and to alleviate further the burden on patients and national healthcare costs.

We look forward to your continued support.

Kazushiro Yamaguchi
President&CEO